Management of Cepacia syndrome in an immunocompetent non-cystic fibrosis adult patient

Int J Infect Dis. 2022 Sep:122:550-552. doi: 10.1016/j.ijid.2022.07.004. Epub 2022 Jul 8.

Abstract

Burkholderia cepacia complex (BCC) is nonfermenting, Gram-negative bacteria known to cause high morbidity and mortality. They commonly affect patients with cystic fibrosis (CF) and are often missed in those without, despite being fatal if left untreated. We report a case of cepacia syndrome in a 42-year-old, immunocompetent man without CF who initially presented with sepsis secondary to pneumonia. Multiple isolates from blood, synovial fluid, and wound swabs grew BCC. Treatment options and management strategies remain poorly understood for BCC in general and in cases without CF in specific. We successfully treated the patient using a combination of intravenous and inhalational antibiotics. This case report elaborates on the disease presentation, investigations, and management strategy employed to treat this rare infection.

Keywords: Burkholderia; Cepacia syndrome; Immunocompetent; Management.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-Bacterial Agents / therapeutic use
  • Burkholderia Infections* / diagnosis
  • Burkholderia Infections* / drug therapy
  • Burkholderia cepacia complex*
  • Cystic Fibrosis* / complications
  • Cystic Fibrosis* / microbiology
  • Fibrosis
  • Humans
  • Male
  • Syndrome

Substances

  • Anti-Bacterial Agents